ArticleBiomolecules & biomedicine2026
Salivary and urinary microRNAs as non-invasive biomarkers of minimal residual disease in pediatric acute lymphoblastic leukemia.
Article in Biomolecules & biomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Salivary and urinary microRNAs as non-invasive biomarkers of minimal residual disease in pediatric acute lymphoblastic leukemia.Biomolecules & biomedicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The measurement of minimal residual disease (MRD) in bone marrow serves as a significant predictor of relapse in acute lymphoblastic leukemia (ALL). MicroRNAs, which are secreted in urine and saliva, typically reflect the cellular state and function, thereby demonstrating potential as non-invasive biomarkers for predicting MRD status. This study aims to evaluate the utility of circulating microRNAs in saliva and urine as MRD biomarkers in pediatric patients with ALL. The study cohort comprised 106 patients under 18 years of age diagnosed with ALL at a national pediatric referral hospital in Lima, Peru. Saliva and urine samples were collected on day 15 of induction chemotherapy. Patients were categorized into high-risk relapse (HRR) and standard/intermediate-risk relapse (SIRR) groups based on their day-15 MRD status. Small RNA sequencing was conducted on six paired samples, while RT-qPCR was performed on 23 paired samples to identify and validate differentially expressed microRNAs. A total of thirty microRNAs were differentially expressed in saliva, and two in urine, both of which were downregulated. In saliva, 22 microRNAs showed significant upregulation. miR-1246, miR-223-3p, and miR-1290 exhibited the highest levels of upregulation in HRR patients (log2 fold change = 4.00, 3.95, and 3.73, respectively). Validation confirmed the upregulation of miR-223-3p (log2 fold change = 1.15, p = 0.034). miR-223-3p, both alone and in combination with miR-1290 and miR-1246, demonstrated optimal performance in distinguishing HRR from SIRR patients (AUC = 0.68, 95% CI: 0.52-0.84; AUC = 0.69, 95% CI: 0.53-0.84, respectively). These preliminary findings indicate that miR-223-3p, whether used independently or in conjunction with miR-1246 and miR-1290, may serve as promising non-invasive MRD biomarkers in pediatric ALL. Further validation in larger patient cohorts is necessary to corroborate these results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.